Robert W. Hesslein
Net Worth
Last updated:
What is Robert W. Hesslein net worth?
The estimated net worth of Mr. Robert W. Hesslein is at least $3,483,239 as of 20 Mar 2023. He owns shares worth $361,788 as insider, has earned $218,201 from insider trading and has received compensation worth at least $2,903,250 in Voyager Therapeutics, Inc..
What is the salary of Robert W. Hesslein?
Mr. Robert W. Hesslein salary is $580,650 per year as Senior Vice President & Gen. Counsel in Voyager Therapeutics, Inc..
How old is Robert W. Hesslein?
Mr. Robert W. Hesslein is 72 years old, born in 1953.
What stocks does Robert W. Hesslein currently own?
As insider, Mr. Robert W. Hesslein owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | Senior Vice President & Gen. Counsel | 102,200 | $3.54 | $361,788 |
What does Voyager Therapeutics, Inc. do?
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Robert W. Hesslein insider trading
Voyager Therapeutics, Inc.
Mr. Robert W. Hesslein has made 13 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 4,410 units of VYGR stock worth $34,222 on 20 Mar 2023.
The largest trade he's ever made was exercising 4,897 units of VYGR stock on 21 Mar 2022. As of 20 Mar 2023 he still owns at least 102,200 units of VYGR stock.
Voyager Therapeutics key executives
Voyager Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Glenn F. Pierce M.D., Ph.D. (69) Independent Director, Interim Chief Scientific Officer & Chief Medical Officer
- Dr. Steven M. Paul M.D. (74) Executive Science Advisor & Director
- Mr. G. Andre Turenne (51) Advisor
- Mr. Michael J. Higgins M.B.A. (63) Interim Chief Executive Officer, Pres & Chairman
- Mr. Robert W. Hesslein (72) Senior Vice President & Gen. Counsel